Table Of Content

AUTHOR INDEX Sampson, W., 595 7. Sargent, D., 222 Sasson, A.R., 1LU7 / Sato, T., 105, 16( Schadendorf, D., Schilsky, R.L., 211 Sigurdson, E.} Small, E.]., Smith, G., Sotsky Spatz, A., Staudt, L.) Seminars in Oncology, Vol 29, No 6 (December), 2002 pp 610-621 AUTHOR INDEX Sampson, W., 595 7. Sargent, D., 222 Sasson, A.R., 1LU7 / Sato, T., 105, 16( Schadendorf, D., Schilsky, R.L., 211 Sigurdson, E.} Small, E.]., Smith, G., Sotsky Spatz, A., Staudt, L.) Seminars in Oncology, Vol 29, No 6 (December), 2002 pp 610-621 SUBJECT INDEX SUBJECT INDEX Abl, 473 Biochet 1otherapy Ab2B, 473 in adjuvant setting, 453 Ab3, 473-474 in melanoma, 457 ABCD rule, 309, 310, 314 in metastatic melanoma, 436-438 Acupuncture, 533-534 outpatient regimens of, 451-452 in prostate cancer, 577 phase III trials of, 452-453 Adaptive immunotherapy, locoregional, 163-164 sequence of, 451 Adenocarcinoma, microscopic profiles of, 42 Biological Adenovirus, replication-deficient, 205-206 163 Adjuvant systemic therapy, 231 American Society for Therapeutic Radiation Onclogy Consensus Panel, 265-266 Amifostine, in metastatic melanoma, 429-430 Amosite, 4, 24 Amphibole fiber, 4 Amsacrine, for mesothelioma, 66 In polychem Analyte-specific reagents, FDA definition of, 299 Bleomycin, vin Anecdotes, informed consent and, 602-603 Angiogenesis, tumor, 375 Anthophyllite, 4 Anti-idiotype network theory, 462-463 Anti-idiotype vaccine, 464-465 in melanoma, 465-467 Anti-idiotypic antibody, mechanism of action of, 4 (Z Antiangiogenic therapy, in metastatic melanoma, 440 c1h emoimmunothej rapy Antibody, as assay reagent, 233 chemotherapy in, 5 Antibody-based fusion protein, mechanism of action of, 4 Antibody-dependent cell-mediated cytotoxicity, 47 Antigen, melanoma, 480-481 managem Antigen-presenting cell, 86 rain irradiation Antioxidants, with chemotherapy and radiotherapy, 54 Antitumor immune response, 83 Arteriovenous shunting, in hepatic arterial therapy, 123 Ashestos experimental models for, exposure to, 4, 6-9 fiber types in, 22-23 human mesothelioma and, 9-10 malignant mesothelioma and, 3-5 occupational exposure to, 19-20 pathogenic mechanisms of, 5 Asbestosis, 3-4 mesothelioma frequency v, 8 Assay, for tumor markers, 215-2 2 1 seroyso statin-1i, . Ayurveda, 537 Butchart staging system, Azacytidine, in combination chemotherapy, 66-67 Aziridinylbenzoquinone, for mesothelioma, 66 c-erbB-2 idjuvant tamoxifen therapy BAGE gene, 480-481 ilkylating went resistance and, Baicalein, 535 analysis methods for, 232-234 BEC2, 466 inthracycline-based therapy and, Best case series as chemotherapy predictive factor, definition of, endocrine therapy response and, studies for, 554- exterea cellOuRlasr .o dlo main of, 122511 .73) Best case series program, 549 as marker, 232 Betulinic acid, 417 marker development of, steps in, 241 Bevacizumab, in mesothelioma, 91-92 potential uses of, as tumor marker, 234 SUBJECT INDEX erbB-2 (Continued Chemotherapy (Continued) as predictive factor, combination, see Polychemotherapy as prognostic factor, 234-235 external-beam radiation therapy and, 199-200 taxanes and, 239 hepatic arterial, see Hepatic arterial infusional trastuzumab and, 239-24 chemotherapy -erbB-2 gene, 2 32 history of, in mesothelioma, 77-78 interferon and, in melanoma, 448-449 interleukin and, in melanoma, 449 in malignant pleural mesothelioma, 62-63 ‘aelyx, for mesothelioma, 63 in melanoma, 396-397 amera dermat« in multimodality therapy, 47-48 vancer neoadjuvant, hepatic resection and, 131 complementary and alternative medicine in, single-agent, 413-417, 427, 446 latai analy| sis in, in stage IV melanoma, 384 DNA microarray in, 280 in unresectable malignant mesothelioma, 97-98 gene - expression patterns Bien , 24Be6 Q11 Chinese Medical Syndrome Classification, 570 psychosocial support in, 396-595 Chinese medicine, see Traditional Chinese medicine “=. specimen selection in, for molecular characterization, 280 Chlorozotocin, in melanoma, 428 stress and, 314 Chromogenic in situ hybridization, 232. ) 233 tumor heterog Chromosome 22, in mesothelioma, 14 -anel, on Complementary and Alternative Chronic lymphocytic leukemia, 260-262 Medicine, 549 molecular diagnosis of, 261 -ancer and Leukemia Group B prognostic scoring system, 38 Chrysotile, 22, 2 ‘ancer germ-line gene, 494 Chymostrypsin, in cancer therapy, 536 ‘ancer Patient Educators Network, 532 CI-980, 416 ‘ancer personality, 596 Cisplatin, 404, 436, 437, 450 “ancer screening in combination chemotherapy, 66-67, definition of, 286 in isolated limb perfusion, 401 tumor markers and, 286-2 for mesothelioma, 63 , uncer \ Vax vaccine, 44 5 > in metastatic melanoma, 429-430 arboplatin in polychemotherapy, for metastatic melanoma, 432 in combination chemotherapy, for mesothelioma, 74-75 Cisplatin, carboplatin regimen, in melanoma, 421 tor mesothelioma, 63 Cisplatin, dacarbazine, carmustine, tamoxifen regimen, in in metastatic melanoma, 429-430 melanoma, 417-420 -arboplatin, cisplatin regimen, in melanoma Zi 1 Cisplatin, dacarbazine, fotemustine, tamoxifen regimen, in farboplatin, dacarbazine, tamoxifen regimen, in melanoma, 421 melanoma, 420 ‘arcinoembryonic antigen, rising, 288 Cisplatin, dacarbazinea, tamoxifen regimen, in melanoma, varmustine 421 in melanoma, 428 Cisplatin, etoposide regimen, in melanoma, 422 in metastatic melanoma, 430 Cisplatin, tamoxifen regimen, in melanoma, 396-397, 420 in polychemotherapy, for metastatic melanoma, 432 Cisplatin, tirapazamine regimen, in melanoma, 422 ‘armustine, dacarbazine, cisplatin, tamoxifen regimen, in Clear cell artifact, 338 melanoma, 417-420 Cochrane Collaboration, 538 "B11, 233 Collin’s formula, 120-12 CI-779, 439 Colon cancer ‘D11 early relapse treatment in, 288-289 ~D40, 375 microsatellite instability in, 214, 227 eee prhes D59, 472-473 p53 and, 250-251 D8 effector response, 86 Colorectal cancer Cell microarray, 284 metastatic, hepatic resection for, 107-108 entral processing unit, 316 recurrence patterns in, 169 *hemoimmunotherapy recurrent hepatic metastases of, 114-115 in brain metastasis, 516 Combination chemotherapy, see Polychemotherapy in malignant mesothelioma, 90-91 Compactness index, 318 regional, 162 Complement-dependent cytotoxicity, 472 ~hemoradiation Complementary and alternative medicine adjuvant, 45-47 in cancer, 531-532 extrapleural pneumonectomy and, 45-47 cancer centers investigating, 549 Chemotherapy in cancer patients, 547 adjuvant, hepatic resection and, 129-131 cancer research of, 546-547 c-erbB-2 and, 2 definition of, 531, 546, 595 SUBJECT INDEX Complementary and alternative medicine (Continued) Cytokine gene transfer future of, in cancer research, 550 in vivo, 506-508 history of, at National Cancer Institute, 550 into allogeneic tumor cells, 505-50¢ information sources about, 537-538 into autologous tumor cells, 504-505 informed consent case studies in, 604-605 into mixed tumor cells, 506 informed consent in, 601-602 into xenogeneic tumor cell, 506 informed consent principle in, 603-604 targeting signal transduction, 508-509 invalid consents in, 605-606 Cytosine deaminase gene, 205 at life’s end, 541-542 Cytotoxicity mandate for, 538-540 antibody-dependent cell-mediated, 472 National Cancer Institute research programs of, 547-55( a complement-dependent, 47 nondisclosure of, 533 oncology informed consent in, 605 Dacarbazine, 404, 436, 4 PDQ evidence levels for, 538 in melanoma, 446 research challenges in, 537 in metastatic melanoma, 41 topics of, in Grant Portfolio, 550 in polychemotherapy, 432 use of, 531 temozolomide v, 428-429 Complementary and alternatiy © medicine cancer information Dacarb zine, bleomycin, vincristine, lomustine regimen, in program, 549-550 melanoma, 422 Complementary and alternative therapy, in prostate cancer, Dacarbazine, carboplatin, tamoxife regimen, in melanoma, 575 421 Computed tomography Dac irbazine, carmustine, cisplatin, tamoxifen regime following chemoembolization, 146 melanoma, 417-420 following radioembolization, 155, 156, 157 Jacarbazine, cisplatin, tamoxifen regimen, in melanoma, 421 following radiofrequency ablation, 173-175 Jacarbazine, fotemustine, cisplatin, tamoxifen regimen, in in hepatic metastasis evaluation, 111-112 melanoma, 420 in malignant pleural mesothelioma, 26-28 Dacarbazine, Genasense regimen, in melanoma, 423 in peritoneal mesothelioma, 54, 55 dacarbazine, vindesine regimen, in melanoma, 421- in peritoneal mesothelioma diagnosis, 53 Jartmouth regimen, 433, 450 Computed tomography arterial portography, in hepatic in melanoma, 417 metastasis evaluation, 112 Dendritic cell, 86, 486-487 Computer-aided topodermatographic image analysis, 319- Yermatoscope, 312 Consent, informed camera, 316 anecdotes and, 602-603 2 Dermatoscopic score index, 315 case studies of, 604-605 Yermatoscopy, 31 in complementary and alternative medicine, 601-602, 603- computer 604 for lesion analysis, 318 invalid, 605-606 naked eye inspection v, liability and, 606 Dermoscopy, 312 CpG DNA, 498 Detorubicin, for mesothelioma, 63 Crocidolite, 4, 24 DETOX, 482 Cryoablation, 185 Dexamethasone, hepatic toxicity and, Cryosurgical ablation, 179, 180-181 Di Bella multitherapy, 536 Cryotherapy Dibromodulcitol, in TI polychemotherapy, for metastatic complications of, 189-190 melanoma, 432 contraindications for, 184 Dichotomized system, 233 current indications for, 183-184 Diffuse large B-cell lymphoma, 259-26 u history of, 183 subtypes of, 260 outcomes following, 186-189 Diffuse malignant pleural mesothelioma physiology and, 185-186 chemotherapy in, 45 recurrence sites following, 189 clinical presentation in, 41 technique for, 184-185 diagnosis of, 41 Crysotile, 4 incidence of, 41 Cutpoint system, 233 microscopic profiles of, 42 Cyclophosphamide multimodality therapy in, 45-48 in combination chemotherapy, 66-67 novel therapies in, 48-49 for mesothelioma, 66 radiation therapy in, 43-45 Cytarabine, in metastatic melanoma, 429-430 staging of, 42-43 Cytokine(s), 438 surgery in, 44-45 in malignant mesothelioma, 85 Digital dermatoscopy, for lesion analysis, 318 in metastatic melanoma, 435, 436 Digital standard dermatoscopic point score, 317 SUBJECT INDEX Floxuridine in hepatic arterial infusional therapy, 120-1 hepatic toxicity of, 131-132 Fluorescent in situ hybridization, 232 ae kits for, 233-23 Fluorouracil, 199-200 Food and Drug Administration mission of, 299-300 premarket approval application, 295 ‘ood and Drug Administration submission inalytical data requirements for, 296-297 clinical data requirements for, for tumor markers, 296-297 teoer ya resourc; es bfoer , 2270 5 metastasis, in metastatic in melanoma, 415-416, 428 mustine, dacarl 1e, cisplatin, tamoxifen regimen, in melanoma, Genetic immunization, Genetics, human mesot Germ cell tumor, e Gibbs-Donnon equilibrium, Ginseng, 534-535 Gleason pattern, 216, Gleevec, 225 Globule, 314 Glycerrhize, 534-535 Gonzalez regimen, 535-536 Granulocyte-macrophage colony-stimulating factor liver metastases and, 164-166 SUBJECT INDEX Granulocyte-macrophage colony-stimulating factor Herbal mixture(s), 534-535 (Continued) for prostate cancer, 534 in malignant mesothelioma, 85 Herbal therapy, in prostate cancer, 577 in melanoma, 395 Herbs, 534-535 Great Britain, mesothelioma mortality in, 23-24 commonly used, for cancer, 565-567 Gruppo Universitario Napoletano 1, ? HercepTest, 233 Herpes simplex virus £IUA29 -LU90)C Hierarchical clustering analysis, DNA microarray a Head, squamous cell carcinoma of, p53 and, 2 Histamine, in phase III trials, 460 Heat shock protein, 89 Home brew assay, 298-299 Hemi-hepatectomy, 113 Hormonal therapy, in metastatic Hepatic arterial infusion, of biological response modifiers, Hydropneumothorax, 33 161-163 Hyperbaric oxygen therapy, 540 Hepatic arterial infusional chemotherapy Hyperthermia, in multimodality arteriovenous shunting in, 122-123 cost of, 131 Idiotype network model, clinical appl delivery mechanism in, 119-120 Ifosfamide drug properties essential in, 122 in combination chemotherapy, 66-6 extrahepatic recurrence and, 132 in melanoma, 428 hepatic toxicity and, 131-132 for mesothelioma, 65 history of, 127 Image, definition of, 310 patient selection for, Image resolution, definition of, 3 pharmacologic principles in, 120-123 Immune response, antitumor, 83 pump placement in, 127-128 Immunization randomized trials of, 128-129 genetic, 509-510 rationale for, 126-127 with recombinant protein, 499 technological solutions for, 124 Immuno(bio)therapy toxicity of, 132> -133 locoregional, for hepatic metastases, 16( + Hepatic artery chemoembolization rationale for, 160 clinical outcomes following, 148-150 Immunoembolization, of hepatic metastases, 164-166 rationale for, 145-148 Immunogene therapyp,y , <2u0 6 Hepatic metastasis Immunogene-based therapy, 504 t disease-free interval and, 110 Immunohistochemistry, distribution of, 112 Immunomodulatory gene therapy, in malignant extrahepatic disease extent in, 108-109, 111-112 mesothelioma, 88 hepatic resection contraindications in, 111 Immunostain, of peritoneal mesothelioma, 57 hepatic resection margins in, 109 Immunostimulant, in malignant mesothelioma, 83 locoregional treatment of, 105-106 Immunotherapy long-term results of, and hepatic resection, 107-108 active, 473-474 natural history of, 107 in malignant mesothelioma, 82-87 negative prognostic factors in, and hepatic resection, 108 in metastatic melanoma, 435-4 number of, and hepatic resection, 110 passive, 471-473 primary tumor stage and, 109 In vitro diagnostic device, 219 prognostic factors in, 108-110 FDA labeling of, 298 recurrent, of colorectal cancer, 114-115 Informed consent size of, 110 case studies in, 604-605 unresectable, 115 in complementary and alternative medicine, 601-602 Hepatic resection invalid, 605-606 adjuvant chemotherapy and, 129 principles in, 603-604 adjuvant therapy and, 115-116 Integrative Medicine Service complications of, 114 administration of, 588 morbidity following, 114 inauguration of, 586 mortality following, 114 inpatient, 586-587 nomenclature in, 112, 113 outpatient, 587-588 j ? operative considerations in, 112-114 outreach educational program in, 588 preoperative evaluation in, 111-112 research in, 588 prognostic factors in, 108-110 steps for, 586 repeat, outcome following, 115 structure of, HER2, 232 Integrin, 374-3 assay for, 215 Interferon assay standardization for, 218 chemotherapy and, in melanoma, 448-449 SUBJECT INDEX Liver (Continued) radiation effects on, 196-197 radiotherapy of, 197-198 segmental anatomy of, 11 segmental v wedge resection of, 113-114 surgery of, see Hepatic resection -obectomy, 113 -omustine in melanoma, 428 in metastatic melanoma, 430 -omustine, bleomycin, vincristine, dacarbha zine melanoma, 422 in mesothelioma, 2y0\ -2299 1 prostate cancer, trasound B-scan pa 24) ive, 242 in melanoma, 342 trials of, in mel ] ique of, In melanoma, , 229 1oscintigrapny, Iz ISIS @1 hLe epcaatai c pSeerrftiussiioorn , 1| 4 Yeural mesothellor ImmMunot pathogenesis of, 5 -derived growth factor prognosis in, 36 progress in, | quality of life in, 98 randomized trials in, 98-99 recurrent, 33 smok'i ng and, 3: -4 { SUBJECT INDEX Malignant mesothelioma (Continued) Melanoma (Continued) unresectable, chemotherapy in, 97-98 micrometastases v macrometastases in, 364 ii vaccine for, 89-90 micrometastasis in, 275- vascular endothelial growth factor in, 91-92 molecular staging in, 374-375 Malignant pleural mesothelioma new chem therapeutic wents in, 439 chest radiography in, 26 new staging in, patholo] gic impli' cations of, m3y7 0 CT in, 26-28 new staging system in, 275-2 diffuse, international staging system for, 32 nitrosourea agents in, 415-416 MRI in, 28-29 node staging in, 364-365 lor. isclaned paramediastin il radiation changes in, 3] ocular, isolated hepatic perfusion tn, PET in, 29-30 paclitaxel, tamoxifen regimen in, 42C right-sided diffuse, 31 paclitaxel in, 416 single-agent chemotherapy in, 62-63 pathologic stage III, 365 staging of, 31-32 pathologically staged, 364 tissue diagnosis of, 30-31 primary ulceration of, 365 TNM stage classification in, 32 proposed stage groupings for Marker, tumor, see Tumor marker(s) regional node recurrence in, Megestrol, in melanoma, 428 revised \ meric in Joint Committee staging system for Melanin pigment network, 312, 314 361-368 Melanoma satellites v in-transit metastases in, 364 screening studies in, 391-392 3 seven-point checklist for, 309, idjuvant systemic therapy for, 383-386 single-agent chemotherap\ adjuvant therapy patient selection in, 389-391 stage grouping tn, 366 American v European perspectives on, 306-307 stage Ill, 371-3 analyzing view of, 310-311 stages | and II, 371 antiangiogenic therapy in, 440 staging changes in, betulinic acid in, 417 superficial spreading, biochemotherapy in, 448-453 surgical excision of bleomycin, vincristine, lomustine, dacarbazine r tamoxifen, cisplatin regimen temozolomide in, 414-415 bryostatin-1 in, 417 thalidomide in, 417 carboplatin in, 429-430 INM classification ot, 362 CI-980 in, 416 tumor microstaging in, cisplatin in, 429-430 ulceration in, cisplatin, carboplatin regimen in, 421 ultrasound follow- cisplatin, etoposide regimen in, 422 ultrasound cisplatin, tirapazamine regimen in, 422 viewing of L clinical diagnosis of, 308-309 vinoreib11i ne, tamoxifen regimen combination chemotherapy in, see Polychemotherapy Melanoma antigen gene-2, 8¢ dacarbazine in, 413-414 Melanoma antigen gene-6, 86 dacarbazine, carboplatin, tamoxifen regimen in, 421 Melanoma cell, genetic targeting dacarbazine, carmustine, cisplatin, tamoxifen regimen in, Melimmune-2, 466 417-420 Melphalan, 404 dacarbazine, cisplatin, tamoxifen regimen in, 421 isolated hepatic perfusion dacarbazine, fotemustine, cisplatin, tamoxifen regimen in, 420 in isolahteedt limb I dacarbazine, Genasense regimen in, 423 Meno l, for mesothelion dacarbazine, vindesine regimen in, 421-422 Mesothelial cell, 2 Dartmouth regimen in, 417 Mesothelioma docetaxel in, 416 asbestos and, 9-10 dolastatin-10 in, 416-417 isbestosis fre yuency EORTC trial in, 457-460 epithe lial, 56, 57 fotemustine in, 415-416 human, and SV40, 10 hormonal therapy in, 431 latency of, 14 immunotherapy in, 435-436, 447-448 malignant, Malignant mesothelioma incidence of, 341, 446 malignant pleural, see Malignant pleural mesothelioma increasing incidence of, 361 multicystic, 2-3 lesion surveillance in, 309 nonoccupational, 20 LU103793 in, 417 occupational asbestos exposure and, 19-20 lymph node metastasis of, 342 peritoneal, see Peritoneal mesothelioma metastasis staging in, 365-366 radiation and, 11 SUBJECT INDEX Metastasis, melanoma, Nutritional supplements, in prostate cancer, 575-577 Methotrexate NY-ESO-1, 494 in combination chemotherapy, 66-67 for mesothelioma, 64-65 Ocular melanoma, isolated hepatic perfusion in, 141-143 MF11-30, 465 Office of Complementary and Alternative Medicine, at Microarray National Cancer Institute, 548-549 cell, 284 OK-432, 163-164 DNA, see DNA microarray Oncogene, 375 tissue, 283 Oncolytic virus, 205-206 Micrometastasis, in melanoma, 275-2 One A7, 466 Microphthalmia transcription factor, Optical coherence tomography, 320-321 Microsatellite instability, 214 Oridonin, 535 in colon cancer, 227 Overall irregularity index, 318 Minigene coding, 499 Oxaliplatin, 79 Misonidazole, external-beam radiation therapy and, in combination chemotherapy, 66-67 Mistletoe Oxford Overview, 219 clinical studies of, 590-59] preclinical studies of, 589-590 P6 acupuncture point, 533-534 toxicity of, p53, 203, 205-206, 225 activation of, 249 analysis of, 249 assay for, 215 motherapy, 66-67 bladder cancer and, 251 for mesothelioma, 63 breast cancer and, 251-2 Mitoxantrone, for mesothelioma, 63 cancer and, 249-250 micrographic surgery, 336-337 colon cancer and, 250- malignant melanoma therapy and, 337- function of, 246-249 modification of lung cancer and, 252 Rush permanent map of, 248 Mole-Analyzer, 31 mutations of, 249-250 M lecul ur predictive significance of, Monitoring, i prognostic significance of, 25 Monochemotherapy, 446 prostate cancer and, 252 in metastatic melanoma, < as screening tool, 253-2 Monoclonal antibody squamous cell carcinoma and, 2 is assay reagent, structure of, 246 mechanism Pab240, 249 Most significant irreg Paclitaxel Multicystic mesothelioma, 2 intraperitoneal, pharmacokinetics of, 57-58 VNAisusiletsi]l ocula]r perit. oneal inon clusior in melanoma, 416, 428 for mesothelioma, 66 National Cancer Institute in metastatic melanoma, 430-431 Complementary and mative medicine research at, 547- Paclitaxel, tamoxifen regimen, in melanoma, 420-421 tiT a lliation ulternative medicine cancer complementary and alternative medicine approaches for, 533 rese arch, in malignant mesothelioma, 98 Physicians Data Query website, 534 Pancreatin, as cancer therapy, 535-536 Jational Center for Complementary a Papain, in cancer therapy, 536 Medic ine, 53 | PC-SPES cancer therapy research of, 540 clinical efficacy of, 579 comprehensive cancer centers of, 540-541 clinical studies of, 579-580 funding history of, 539 preclinical studies of, 577-579 phase II-III randomized controlled trials of, 541 recent developments in, 581-582 specialized grant centers of, 540-542 toxicity of, 581 Neck, squamous cell carcinoma of, p PC-SPES herbal mixture, 534 Neurofibromatosis 2 tumor-supressor g Pemetrexed, in combination chemotherapy, 78-79 Nevus, 313 Percutaneous alcohol ablation Nitrogen mustard, 404 complications of, 193 Nitrosourea agents, in metastatic melanoma, 415-416 response following, 192-193 t mesothelioma, 83 results of, 193-194 technique for, 192